Clinical Potential of MicroRNAs in Pancreatic Ductal Adenocarcinoma

Abstract excerpt

OBJECTIVES: Aggressive invasion and early metastases are characteristic features of pancreatic ductal adenocarcinoma (PDAC). More than 90% of patients have surgically nonresectable disease at presentation. Despite increasing knowledge of the genetics of this complex disease, systemic therapies, particularly gemcitabine, have modest clinical benefit and marginal survival advantage. MicroRNAs have been shown to...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Extracellular vesicles in disease
• Share to MicroRNA in disease regulation
• Share to Pancreatic and Hepatic Oncology Research